vida: extract claims from 2026-05-03-vigibase-pharmacovigilance-glp1-psychiatric-signals

- Source: inbox/queue/2026-05-03-vigibase-pharmacovigilance-glp1-psychiatric-signals.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 4
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap.md

@@ -11,9 +11,16 @@ sourced_from: health/2025-truveta-ispor-glp1-discontinuation-reasons.md
 scope: correlational
 sourcer: Truveta Research
 supports: ["behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"]
-related: ["glp-1-access-structure-inverts-need-creating-equity-paradox", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence", "glp1-long-term-persistence-ceiling-14-percent-year-two", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation"]
+related: ["glp-1-access-structure-inverts-need-creating-equity-paradox", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence", "glp1-long-term-persistence-ceiling-14-percent-year-two", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-persistence-improves-with-specialist-care-supporting-obesity-medicine-infrastructure"]
 ---
 
 # GLP-1 discontinuation is 12 percent higher among patients with psychiatric medication history creating an access-adherence trap where highest-need populations have lowest persistence
 
 Truveta's analysis of real-world GLP-1 discontinuation patterns found that patients with a history of psychiatric medication use are 12 percent more likely to discontinue GLP-1 therapy compared to those without psychiatric history. This creates a compounding access-adherence trap: patients with co-occurring mental health and metabolic conditions face the highest obesity burden and metabolic disease risk, yet are systematically less likely to both access GLP-1s (due to income and coverage barriers documented in KFF data) AND maintain therapy when they do gain access. The psychiatric comorbidity effect operates independently of income, age, and other comorbidity factors, suggesting a distinct mechanism—potentially related to medication burden, side effect tolerance, or behavioral health system fragmentation. This finding reveals that the population most likely to benefit from GLP-1 therapy (those with multiple chronic conditions including mental health disorders) faces a double barrier: structural access limitations followed by adherence failure even when access is achieved.
+
+
+## Extending Evidence
+
+**Source:** VigiBase study, Clinical Nutrition 2025
+
+Concurrent prescribing analysis shows OR 4.45 for suicidal ideation reports with antidepressants and OR 4.07 with benzodiazepines. The highest-risk patients are those with pre-existing psychiatric pharmacotherapy, creating a safety-persistence paradox: the patients most likely to discontinue (psychiatric comorbidity) are also those with highest adverse event reporting rates.

domains/health/glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population.md

@@ -12,7 +12,7 @@ scope: causal
 sourcer: NIH / JAMA Psychiatry
 supports: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation"]
 challenges: ["the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served rather than expanding access"]
-related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population"]
+related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"]
 ---
 
 # GLP-1 receptor agonists demonstrate NNT 4.3 for alcohol use disorder in adults with comorbid obesity — superior to all approved AUD medications
@@ -32,3 +32,10 @@ Expert consensus from Science Media Centre reactions confirms SEMALCO trial limi
 **Source:** eClinicalMedicine meta-analysis, 2025
 
 Meta-analysis demonstrates effect extends beyond comorbid obesity population to general metabolic patients (T2D/obesity) prescribed GLP-1s for metabolic indications, not AUD treatment. This suggests the mechanism is not limited to the obesity-AUD comorbidity subset but operates across metabolic patient populations.
+
+
+## Challenging Evidence
+
+**Source:** VigiBase study, Clinical Nutrition 2025
+
+VigiBase pharmacovigilance analysis shows eating disorder signals with aROR 4.17-6.80 across all three GLP-1 RAs (semaglutide, dulaglutide, liraglutide), suggesting GLP-1's appetite suppression mechanism may precipitate eating disorder pathology in vulnerable individuals. This is a class effect, not drug-specific, indicating the reward pathway modulation that benefits AUD may create eating disorder risk in susceptible populations.

domains/health/semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism.md

@@ -17,3 +17,10 @@ related: ["the-mental-health-supply-gap-is-widening-not-closing-because-demand-o
 # Semaglutide reduces depression worsening by 44 percent in patients with pre-existing depression through GLP-1R-mediated psychiatric protective effects
 
 A Swedish national cohort study of 95,490 adults with diagnosed depression, anxiety, or both found semaglutide associated with 44% lower risk of worsening depression (aHR 0.56) and 38% lower risk of worsening anxiety compared to other antidiabetic medications. The study used an active-comparator design comparing GLP-1 RAs to other antidiabetic drugs, minimizing healthy-user bias that plagued earlier observational studies. Critically, the effect was drug-specific: liraglutide showed only 18% risk reduction, while exenatide and dulaglutide showed no significant effect. This within-class variation suggests the mechanism is not simply GLP-1 class effect but relates to semaglutide-specific properties—possibly higher GLP-1R agonism potency or superior CNS penetration. The study explicitly addresses the indication bias problem that affected the Session 34 '195% MDD risk' finding: by comparing GLP-1 users to other diabetic medication users (not untreated controls), it controls for the confounding where people with worse metabolic health have higher baseline depression rates. The magnitude of effect (44% reduction) is clinically substantial, not marginal. Multiple expert reactions confirmed methodological credibility despite observational design. This represents the strongest counter-evidence to GLP-1 psychiatric safety concerns and suggests GLP-1R agonism produces psychiatric protective effects independent of metabolic improvement.
+
+
+## Challenging Evidence
+
+**Source:** VigiBase study, Clinical Nutrition 2025
+
+VigiBase disproportionality analysis shows semaglutide-specific signals for depressed mood (aROR 1.70), suicidality (aROR 1.45), and anxiety (aROR 1.26). Only semaglutide showed signals in BOTH FAERS and VigiBase for depression. Liraglutide and tirzepatide showed NO significant depressive disorder signals. This contradicts the Swedish cohort protective finding and suggests semaglutide may have drug-specific psychiatric risks not shared by other GLP-1 RAs.

inbox/archive/health/2026-05-03-vigibase-pharmacovigilance-glp1-psychiatric-signals.md

@@ -7,10 +7,13 @@ date: 2025-12-01
 domain: health
 secondary_domains: []
 format: research-article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-03
 priority: medium
 tags: [GLP-1, semaglutide, psychiatric-safety, pharmacovigilance, vigibase, adverse-events, depression, suicidality, eating-disorders]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content